Showing 8 of 8 recruiting trials for “Idiopathic multidrug-resistant nephrotic syndrome”
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
👨⚕️ William A Gahl, M.D., National Human Genome Research Institute (NHGRI)📍 1 site📅 Started Apr 2026View details ↗
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
AMPK-activation by Metformin in FSGS: AMP-FSGS
RecruitingNCT05650619 ↗
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
👨⚕️ Jeffrey I Silberzweig, MD, Weill Medical College of Cornell University📍 12 sites📅 Started May 2015View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →